Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
J&J bispecific combo delivers 89% PFS benefit in myeloma
An 89% progression-free survival improvement and a 62% overall survival benefit topline Tecvayli and Talvey’s MonumenTAL-6 readout in earlier myeloma.
Angus Liu
Jul 23, 2026 8:30am
Access: A key driver of non-opioid pain management adoption
Brought to you by
Pacira BioSciences, Inc.
Durable IBD remission remains an unmet need: survey
Jul 24, 2026 2:07pm
Peptide adcomm Day 2: Emideltide fails to make grade in vote
Jul 24, 2026 2:00pm
The Oral GLP-1 Tracker: Obesity prescriptions jump
Jul 24, 2026 11:00am
Ipsen's liver disease drug Bylvay fails biliary atresia trial
Jul 24, 2026 11:00am
More News
Amgen submits analyses to FDA in bid for Tavneos hearing
Jul 24, 2026 10:50am
Novo escalates Lilly ad suit, plans bid to halt comparative ads
Jul 24, 2026 10:45am
Merck prepares expanded access to monthly PrEP pill early
Jul 24, 2026 10:40am
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 2026 9:42am
